Pfizer’s COVID-19 antiviral Paxlovid cut the prevalence of hospitalizations and deaths in half when it was used within the first day of diagnosis, according to a study published Dec. 16 in Nature.
Read the full post on Becker's Hospital Review - Healthcare News
